Welcome to our dedicated page for CALITHERA BIOSCIENCES news (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on CALITHERA BIOSCIENCES stock.
Calithera Biosciences Inc. (CALA) is a pioneering biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule drugs aimed at slowing tumor growth. Their approach focuses on controlling key metabolic pathways in both tumor and immune cells, targeting the distinct metabolic requirements of these cells to impede cancer proliferation.
Calithera leverages the promising fields of tumor metabolism and tumor immunology to create new, innovative cancer therapies. Recent clinical successes highlight the potential of their investigational medicines to slow abnormal cell growth and offer fundamentally new treatment options for cancer patients.
Currently, Calithera's lead candidate is in Phase 2 trials for patients with renal cell carcinoma and triple negative breast cancer. These trials are crucial given the urgent need for new treatments in these solid tumors.
Calithera also engages in strategic partnerships to bolster its research and development efforts. Their onco-metabolism approach aims to bring a fresh perspective to cancer treatment by exploiting the unique metabolic needs of cancer cells versus cancer-fighting immune cells.
For more information, latest updates, and significant news regarding Calithera Biosciences Inc., visit their official webpage or contact them directly.
Calithera Biosciences (Nasdaq: CALA) announced the presentation of a poster on the Phase 1b study design for CB-280, its arginase inhibitor, at the North American Cystic Fibrosis Virtual Conference. The study evaluates CB-280's safety and efficacy in adults with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Preliminary results show improved lung function in preclinical models. Calithera is optimistic about CB-280's potential and plans to share interim data in 2021.
Calithera Biosciences (CALA) has initiated a randomized Phase 2 clinical trial called KEAPSAKE to assess the safety and efficacy of its glutaminase inhibitor, telaglenastat, in combination with standard treatments for stage IV non-small cell lung cancer (NSCLC) patients harboring KEAP1/NRF2 mutations. This study will enroll about 120 patients and aims to evaluate progression-free survival. Preclinical data suggests that tumors with these mutations are highly dependent on glutaminase, making them sensitive to telaglenastat. Interim results are expected in 2021.
Calithera Biosciences (Nasdaq: CALA) announced its participation in four upcoming virtual healthcare investor conferences, enhancing investor engagement. The key presentations include:
- Citi’s 15th Annual Biopharma Virtual Conference: Susan M. Molineaux will present on Sept 9, 2020, at 11:40 a.m. ET.
- Wells Fargo Virtual Healthcare Conference: Molineaux will be featured on Sept 10, 2020, at 11:20 a.m. ET.
- H.C. Wainwright & Co. Conference: Presentation on Sept 16, 2020, at 9:30 a.m. ET.
- Cantor Virtual Global Healthcare Conference: Presentation on Sept 17, 2020, at 2:40 p.m. ET.
Calithera Biosciences (CALA) announced the granting of a non-qualified stock option to a new employee for 8,000 shares at an exercise price of $4.03, reflecting the closing stock price on August 31, 2020. The option will vest incrementally, with one-fourth vested in August 2021 and the remainder over thirty-six months. This decision aligns with Calithera's 2018 Inducement Plan and Nasdaq rules. Calithera focuses on developing targeted cancer therapies and acknowledges that forward-looking statements regarding its products entail risks and uncertainties that could affect its stock performance.
Calithera Biosciences reported its Q2 2020 financial results, revealing a cash position of $154.1 million. The clinical-stage biotechnology company announced advances in its drug development, including the initiation of a Phase 1b trial for its arginase inhibitor in cystic fibrosis. The pivotal CANTATA trial on renal cell carcinoma is set to report top-line results in late 2020 or early 2021. Q2 net loss was $20.4 million, or $0.29 per share, with a decrease in R&D expenses from $20.9 million in 2019 to $15.7 million in 2020.
Calithera Biosciences (Nasdaq: CALA) announced the granting of a non-qualified stock option for 30,000 shares at an exercise price of $4.70 to a new employee, effective July 31, 2020. The option vests in four phases, with one-fourth vesting in July 2021 and the remainder over the next three years. This grant aligns with the Inducement Plan approved by the board in January 2018 and follows Nasdaq Listing Rule 5635(c)(4). Calithera focuses on developing targeted therapies for cancer treatment, emphasizing its commitment to improving patient outcomes.
Calithera Biosciences (CALA) announced its second quarter 2020 financial results will be released on August 10, 2020. Management will hold a conference call at 2:00 p.m. Pacific Time to discuss the results and corporate highlights. The company is focused on developing small molecule drugs for cancer treatment and has a pipeline of first-in-clinic oral therapeutics. The press release emphasizes the company's commitment to improving patient outcomes and highlights the importance of ongoing clinical trials for product candidates.
Calithera Biosciences has appointed Scott Garland to its board of directors, bringing 29 years of biopharmaceutical experience. Garland previously served as the president and CEO of Portola Pharmaceuticals and has significant expertise in oncology. His leadership comes at a crucial time as Calithera aims to advance its product telaglenastat towards market readiness. Garland's extensive background includes roles in marketing and sales at major companies like Relypsa and Genentech, where he led the launches of key therapies. This appointment is viewed positively as Calithera expands its clinical programs.
Calithera Biosciences (CALA) has initiated the first patient dosing in a Phase 1b clinical trial for the arginase inhibitor CB-280 aimed at treating cystic fibrosis (CF) and chronic airway infection. This randomized, double-blind study will assess CB-280’s safety and optimal dose when combined with existing CF treatments. Previous research indicates that arginase activity negatively impacts lung function in CF patients. The trial involves 32 adult patients and follows a Phase 1 study that confirmed CB-280's safety in healthy volunteers. Calithera retains rights to develop CB-280 for specific non-oncology indications.
Calithera Biosciences (CALA) announced the grant of non-qualified stock options totaling 14,500 shares to two new employees. The options have an exercise price of $5.28, equal to the closing price on June 30, 2020. Vesting is set at one-fourth in June 2021, followed by 36 monthly installments. This move is part of the company's 2018 Inducement Plan, aligning with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent. Calithera focuses on developing therapies that target cancer and other life-threatening diseases, emphasizing the importance of innovative treatments.
FAQ
What is the market cap of CALITHERA BIOSCIENCES (CALA)?
What does Calithera Biosciences Inc. specialize in?
What is the primary focus of Calithera's research?
What are Calithera's lead candidates currently being tested for?
How does Calithera's onco-metabolism approach work?
What recent achievements has Calithera accomplished?
Who can I contact for more information about Calithera?
Where can I find the latest updates on Calithera?
What kind of partnerships does Calithera engage in?
Why is Calithera's research important?
What makes Calithera's therapy approach unique?
